{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:16:28Z","timestamp":1788236188658,"version":"build-2803163510"},"reference-count":128,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 DK007634"],"award-info":[{"award-number":["T32 DK007634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clinthera.2023.09.017","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T07:05:04Z","timestamp":1701673504000},"page":"1189-1200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease"],"prefix":"10.1016","volume":"45","author":[{"given":"Ellen W.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle S.","family":"Byers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0923-4300","authenticated-orcid":false,"given":"Sasha","family":"Deutsch-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.09.017_bib0001","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.29887","article-title":"The high burden of alcoholic cirrhosis in privately insured persons in the United States","volume":"68","author":"Mellinger","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0002","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0004","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.cgh.2022.03.017","article-title":"Alcohol-associated liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic","volume":"20","author":"Deutsch-Link","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0005","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0006","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/acer.13944","article-title":"Gender disparities in alcohol use disorder treatment among privately insured patients with alcohol-associated cirrhosis","volume":"43","author":"Mellinger","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.10.026","article-title":"Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group","volume":"19","author":"Im","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0008","series-title":"Diagnostic and Statistical Manual of Mental Disorders","article-title":"Substance-related and addictive disorders","year":"2022"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0009","unstructured":"National Institute on Alcohol Abuse and Alcoholism. Drinking Levels Defined [NIAAA website]. Available at: https:\/\/www.niaaa.nih.gov\/alcohol-health\/overview-alcohol-consumption\/moderate-binge-drinking. Accessed May 13, 2023."},{"key":"10.1016\/j.clinthera.2023.09.017_bib0010","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jama.2018.16789","article-title":"Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0011","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0012","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11606-009-0928-6","article-title":"Primary care validation of a single-question alcohol screening test","volume":"24","author":"Smith","year":"2009","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0013","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"for the Ambulatory Care Quality Improvement Project (ACQUIP). The AUDIT Alcohol Consumption Questions (AUDIT-C): an effective brief screening test for problem drinking","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0014","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s11606-015-3391-6","article-title":"Validation of self-administered Single-Item Screening Questions (SISQs) for unhealthy alcohol and drug use in primary care patients","volume":"30","author":"McNeely","year":"2015","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0015","unstructured":"Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care, ed 2. Geneva: World Health Organization; 2001."},{"key":"10.1016\/j.clinthera.2023.09.017_bib0016","doi-asserted-by":"crossref","first-page":"879","DOI":"10.7326\/0003-4819-149-12-200812160-00007","article-title":"Meta-analysis: are 3 questions enough to detect unhealthy alcohol use?","volume":"149","author":"Kriston","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0017","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0422","article-title":"Alcohol withdrawal rates in hospitalized patients during the COVID-19 pandemic","volume":"4","author":"Sharma","year":"2021","journal-title":"JAMA Network Open"},{"issue":"3S","key":"10.1016\/j.clinthera.2023.09.017_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0000000000000668","article-title":"The ASAM clinical practice guideline on alcohol withdrawal management","volume":"14","author":"Alvanzo","year":"2020","journal-title":"J Addict Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2018.10574","article-title":"Will this hospitalized patient develop severe alcohol withdrawal syndrome?: the rational clinical examination systematic review","volume":"320","author":"Wood","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0021","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association. Substance-related and addictive disorders","year":"2013"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0022","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.alcohol.2014.01.004","article-title":"The Prediction of Alcohol Withdrawal Severity Scale (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome","volume":"48","author":"Maldonado","year":"2014","journal-title":"Alcohol."},{"key":"10.1016\/j.clinthera.2023.09.017_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/alcalc\/agv043","article-title":"Prospective validation study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in medically ill inpatients: a new scale for the prediction of complicated alcohol withdrawal syndrome","volume":"50","author":"Maldonado","year":"2015","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0024","series-title":"ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions","author":"Mee-Lee","year":"2013"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0025","unstructured":"Rahman A, Paul M. Delirium Tremens [StatPearls online]. (2023) Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482134. Accessed July 3, 2023."},{"key":"10.1016\/j.clinthera.2023.09.017_bib0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG clinical guideline: alcoholic liver disease","volume":"113","author":"Singal","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0027","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0028","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jnnp.2007.128322","article-title":"The alcohol withdrawal syndrome","volume":"79","author":"McKeon","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0029","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cld.742","article-title":"Misconception: you can't have liver disease with normal liver chemistries","volume":"12","author":"Lominadze","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0030","doi-asserted-by":"crossref","first-page":"e16270","DOI":"10.1097\/MD.0000000000016270","article-title":"Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice","volume":"98","author":"Yen","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0031","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hep4.1841","article-title":"Fibrosis-4 Index as an independent predictor of mortality and liver-related outcomes in NAFLD","volume":"6","author":"Vieira Barbosa","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0032","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"Bataller","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0033","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0034","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2018.04.009","article-title":"Outcomes of early liver transplantation for patients with severe alcoholic hepatitis","volume":"155","author":"Lee","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/archinte.164.13.1405","article-title":"Management of alcohol withdrawal delirium. An evidence-based practice guideline","volume":"164","author":"Mayo-Smith","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0036","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical practice guidelines: management of alcohol-related liver disease","volume":"69","author":"Thursz","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005063.pub3","article-title":"Benzodiazepines for alcohol withdrawal","author":"Amato","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0038","unstructured":"Department of Veterans Affairs, Department of Defense. VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders [Department of Veterans Affairs website]. 2015. Available at: https:\/\/www.healthquality.va.gov\/guidelines\/mh\/sud\/vadodsudcpgrevised22216.pdf. Accessed June 15, 2023."},{"key":"10.1016\/j.clinthera.2023.09.017_bib128","unstructured":"Veterans Health Administration. Alcohon. P&T approved August 25, 2021. Last reviewed March 23, 2023."},{"key":"10.1016\/j.clinthera.2023.09.017_bib114","series-title":"The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions","author":"Mee-Lee","year":"2013"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0039","first-page":"253","article-title":"Alcohol withdrawal syndrome: outpatient management","volume":"104","author":"Tiglao","year":"2021","journal-title":"Am Fam Pract"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0040","series-title":"Presented at: ASAM 2023 Annual Scientific Meeting","article-title":"Management of alcohol withdrawal in the outpatient and detoxification unit setting","author":"Pueringer","year":"2023"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0041","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1345\/aph.1G243","article-title":"Valproic acid management of acute alcohol withdrawal","volume":"40","author":"Lum","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0042","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","article-title":"Gabapentin for the treatment of alcohol use disorder","volume":"27","author":"Mason","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0043","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0045","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/hep4.2080","article-title":"Naltrexone for alcohol use disorder: hepatic safety in patients with and without liver disease","volume":"6","author":"Ayyala","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0053","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [National Institute of Diabetes and Digestive and Kidney Diseases website]. (2020). Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/?report=reader. Accessed July 7, 2023."},{"issue":"1-3","key":"10.1016\/j.clinthera.2023.09.017_bib0054","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","article-title":"Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty","volume":"99","author":"Mark","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0046","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0047","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","article-title":"State-of-the-art behavioral and pharmacological treatments for alcohol use disorder","volume":"45","author":"Ray","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0048","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","article-title":"Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice","volume":"34","author":"Tyson","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0049","doi-asserted-by":"crossref","first-page":"649","DOI":"10.15288\/qjsa.1967.28.649","article-title":"Sudden death during disulfiram\u2014alcohol reaction","volume":"28","author":"Amador","year":"1967","journal-title":"Q J Stud Alcohol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0050","doi-asserted-by":"crossref","first-page":"572","DOI":"10.15288\/jsad.2019.80.572","article-title":"Adherence across FDA-approved medications for alcohol use disorder in a Veterans Administration population","volume":"80","author":"Walker","year":"2019","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0051","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1530-0277.2000.tb02048.x","article-title":"Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence","volume":"24","author":"Johnson","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0052","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2023.09.017_bib115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-018-1242-0","article-title":"Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis","volume":"17","author":"Bolton","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0055","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0168-8278(97)80355-8","article-title":"Effect of liver cirrhosis on the systemic availability of naltrexone in humans","volume":"27","author":"Bertolotti","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib116","unstructured":"Center for Substance Abuse Treatment. Incorporating Alcohol Pharmacotherapies Into Medical Practice. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2009. (Treatment Improvement Protocol (TIP) Series, No. 49.) Chapter 5\u2014Extended-Release Injectable Naltrexone. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64031\/"},{"key":"10.1016\/j.clinthera.2023.09.017_bib117","unstructured":"Center for Substance Abuse Treatment. Incorporating Alcohol Pharmacotherapies Into Medical Practice. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2009. (Treatment Improvement Protocol (TIP) Series, No. 49.) Chapter 3\u2014Disulfiram. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64036\/"},{"issue":"1","key":"10.1016\/j.clinthera.2023.09.017_bib118","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol\u2010associated liver diseases: 2019 practice guidance from the american association for the study of liver diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0056","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF03033315","article-title":"Role of GABAB receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics","volume":"6","author":"Colombo","year":"2004","journal-title":"Neurotox Res"},{"issue":"9603","key":"10.1016\/j.clinthera.2023.09.017_bib0057","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0058","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0059","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0060","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.247","article-title":"Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations","volume":"54","author":"Vlavonou","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0061","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0062","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.clinthera.2023.09.017_bib123","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.32378","article-title":"AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis","volume":"76","author":"Rogal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib122","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/JEP.S124391","article-title":"Review about gabapentin misuse, interactions, contraindications and side effects","author":"Quintero","year":"2017","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0063","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0064","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","article-title":"Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial","volume":"168","author":"Johnson","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0065","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"10.1016\/j.clinthera.2023.09.017_bib121","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eplepsyres.2014.03.011","article-title":"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment","volume":"108","author":"Manitpisitkul","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4137\/JCNSD.S4365","article-title":"Topiramate: safety and efficacy of its use in the prevention and treatment of migraine","volume":"3","author":"Minton","year":"2011","journal-title":"J Cent Nerv Syst Dis"},{"issue":"10037","key":"10.1016\/j.clinthera.2023.09.017_bib0066","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0067","doi-asserted-by":"crossref","first-page":"19r12924","DOI":"10.4088\/JCP.19r12924","article-title":"The impact of varenicline on alcohol consumption in subjects with alcohol use disorders: systematic review and meta-analyses","volume":"81","author":"Gandhi","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.clinthera.2023.09.017_bib119","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.296.1.64","article-title":"Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial","volume":"296","author":"Tonstad","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0068","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41380-019-0598-7","article-title":"Novel role for mineralocorticoid receptors in control of a neuronal phenotype","volume":"26","author":"McCann","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0069","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1038\/s41380-022-01736-y","article-title":"Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.alcohol.2010.01.002","article-title":"Serotonin-3 receptors in the posterior ventral tegmental area regulate ethanol self-administration of alcohol-preferring (P) rats","volume":"44","author":"Rodd","year":"2010","journal-title":"Alcohol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0071","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0072","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/acer.14932","article-title":"A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder","volume":"46","author":"Seneviratne","year":"2022","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0073","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","article-title":"Effect of naltrexone and ondansetron on alcohol cue\u2013induced activation of the ventral striatum in alcohol-dependent people","volume":"65","author":"Myrick","year":"2008","journal-title":"Arch Gen Psychiatry"},{"issue":"1-2","key":"10.1016\/j.clinthera.2023.09.017_bib0074","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.02.012","article-title":"Walker BM. \u03ba-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats","volume":"61","author":"Nealey","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of \u03ba-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0076","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0077","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001924","article-title":"Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials","volume":"12","author":"Palpacuer","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0079","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146562","article-title":"Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1","volume":"1727","author":"Jerlhag","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0081","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0082","doi-asserted-by":"crossref","unstructured":"Chuong V, Farokhnia M, Khom S, et\u00a0al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 8:e170671.","DOI":"10.1172\/jci.insight.170671"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0083","doi-asserted-by":"crossref","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et\u00a0al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. [J Hepatol website]. 2023. Available at: https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003. Accessed September 12, 2023.","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0084","first-page":"161","article-title":"Admission alcohol level: a predictor of the course of alcohol withdrawal","volume":"33","author":"Vinson","year":"1991","journal-title":"J Fam Pract"},{"issue":"5","key":"10.1016\/j.clinthera.2023.09.017_bib125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00003088-198713050-00001","article-title":"Clinical pharmacokinetics of ethanol","volume":"13","author":"Holford","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0085","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/add.12402","article-title":"Ethyl glucuronide in hair and fingernails as a long-term alcohol biomarker","volume":"109","author":"Berger","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0086","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/alcalc\/ags010","article-title":"Comparison of ethyl glucuronide in hair with self-reported alcohol consumption","volume":"47","author":"Lees","year":"2012","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0087","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/acer.14512","article-title":"Diagnostic accuracy of biomarkers of alcohol use in patients with liver disease: a systematic review","volume":"45","author":"Arnts","year":"2021","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0088","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1530-0277.2012.01855.x","article-title":"Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients","volume":"37","author":"Stewart","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0089","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/lt.23881","article-title":"Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available","volume":"20","author":"Piano","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0090","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/hep.24596","article-title":"Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption","volume":"54","author":"Staufer","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0091","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/alcalc\/agh003","article-title":"Alling C. Phosphatidylethanol formation and degradation in human and rat blood","volume":"39","author":"Arad\u00f3ttir","year":"2004","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0092","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00414-016-1445-x","article-title":"Phosphatidylethanol (PEth) detected in blood for 3 to 12 days after single consumption of alcohol-a drinking study with 16 volunteers","volume":"131","author":"Schr\u00f6ck","year":"2017","journal-title":"Int J Legal Med"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0093","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/acer.12442","article-title":"Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease","volume":"38","author":"Stewart","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0094","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/tri.12949","article-title":"Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study","volume":"30","author":"Andresen-Streichert","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/acer.14786","article-title":"Positive blood phosphatidylethanol concentration is associated with unfavorable waitlist-related outcomes for patients medically appropriate for liver transplantation","volume":"46","author":"Faulkner","year":"2022","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0096","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/acer.13558","article-title":"Applications and challenges for the use of phosphatidylethanol testing in liver disease patients (mini review)","volume":"42","author":"Nguyen","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0097","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/lt.26297","article-title":"Is blood transfusion a means of false positive phosphatidylethanol testing?","volume":"28","author":"Bhavsar-Burke","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0098","unstructured":"Substance Use Disorder Treatment for People With Co-Occurring Disorders [Substance Abuse and Mental Health Services Administration website]. 2020. Available at: https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP20-02-01-004_Final_508.pdf. Accessed June 15, 2023."},{"key":"10.1016\/j.clinthera.2023.09.017_bib126","series-title":"No","article-title":"Substance Use Disorder Treatment for People With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series","volume":"42","author":"Substance Abuse and Mental Health Services Administration","year":"2020"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0099","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cld.1204","article-title":"Psychiatric disorders and their treatment: impact of outcomes in patients with chronic liver disease","volume":"20","author":"Holmes","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cgh.2015.07.047","article-title":"Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease\u2014a systematic review","volume":"14","author":"Khan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0101","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.psym.2019.12.004","article-title":"Confronting the crisis of comorbid alcohol use disorder and alcohol-related liver disease with a novel multidisciplinary clinic","volume":"61","author":"Winder","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0102","series-title":"Presented at: ASAM 2023 Annual Scientific Meeting","article-title":"Addiction treatment in alcohol associated liver disease","author":"Anand","year":"2023"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0103","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2016.04.029","article-title":"Treatment of alcohol use disorders in patients with alcoholic liver disease","volume":"65","author":"Addolorato","year":"2016","journal-title":"J Hepatology"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0104","doi-asserted-by":"crossref","first-page":"e00145","DOI":"10.1097\/HC9.0000000000000145","article-title":"Management of alcohol use disorder in patients with chronic liver disease","volume":"7","author":"Mellinger","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0105","article-title":"Effectiveness of brief alcohol interventions in primary care populations","volume":"2","author":"Kaner","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0106","volume":"3","author":"Miller","year":"2012"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/acer.13911","article-title":"The role of social support in motivating reductions in alcohol use: a test of three models of social support in alcohol-impaired drivers","volume":"43","author":"Moon","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0108","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.4254\/wjh.v14.i10.1875","article-title":"Alcohol use disorder and liver injury related to the COVID-19 pandemic","volume":"14","author":"Marano","year":"2022","journal-title":"World J Hepatol"},{"issue":"6","key":"10.1016\/j.clinthera.2023.09.017_bib127","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.18045","article-title":"Expansion of telehealth availability for mental health care after state-level policy changes from 2019 to 2022","volume":"6","author":"McBain","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0109","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.5114\/aoms.2014.47829","article-title":"New diagnostic criteria for alcohol use disorders and novel treatment approaches\u20142014 update","volume":"10","author":"Tyburski","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0110","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/j.1530-0277.2007.00536.x","article-title":"Rates and correlates of relapse among individuals in remission from DSM-IV alcohol dependence: a 3-year follow-up","volume":"31","author":"Dawson","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.04.003","article-title":"Predicting relapse after alcohol use disorder treatment in a high-risk cohort: the roles of anhedonia and smoking","volume":"126","author":"Nguyen","year":"2020","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0112","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/add.15959","article-title":"Duration of medication treatment for opioid-use disorder and risk for overdose among Medicaid enrollees in 11 states: a retrospective cohort study","volume":"117","author":"Burns","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2023.09.017_bib0113","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:53Z","timestamp":1758963533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823003806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":128,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0149291823003806"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}